Literature DB >> 12034786

Increased risk of Parkinson's disease after depression: a retrospective cohort study.

A G Schuurman1, M van den Akker, K T J L Ensinck, J F M Metsemakers, J A Knottnerus, A F G Leentjens, F Buntinx.   

Abstract

BACKGROUND: Depression has been linked to the occurrence of a number of somatic diseases. There are no data for PD.
OBJECTIVE: To determine if depression is associated with a subsequent risk for PD.
METHODS: A retrospective cohort study design based in general practice was applied. All subjects diagnosed with depression between 1975 and 1990 were included and matched with subjects with the same birth year who were never diagnosed with depression. Follow-up ended at April 30, 2000. Hazard ratios (HR) and 95% CI were calculated using Cox proportional hazards models adjusted for age, sex, and socioeconomic status. Subgroups based on sex and age at diagnosis of depression were evaluated separately.
RESULTS: Among the 1,358 depressed subjects, 19 developed PD, and among the 67,570 nondepressed subjects, 259 developed PD. The HR (95% CI) for depressed vs nondepressed subjects was 3.13 (1.95 to 5.01) in multivariable analysis. Associations in subgroups were comparable with the overall association.
CONCLUSION: A strong positive association was found between depression and subsequent incidence of D.

Entities:  

Mesh:

Year:  2002        PMID: 12034786     DOI: 10.1212/wnl.58.10.1501

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

Review 1.  Premotor Diagnosis of Parkinson's Disease.

Authors:  Heinz Reichmann
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 3.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 4.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

5.  Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder.

Authors:  Mohammad M Herzallah; Ahmed A Moustafa; Joman Y Natsheh; Omar A Danoun; Jessica R Simon; Yasin I Tayem; Mahmud A Sehwail; Ivona Amleh; Issam Bannoura; Georgios Petrides; Catherine E Myers; Mark A Gluck
Journal:  J Affect Disord       Date:  2013-08-13       Impact factor: 4.839

6.  Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.

Authors:  Lori M Gorton; Marta G Vuckovic; Nina Vertelkina; Giselle M Petzinger; Michael W Jakowec; Ruth I Wood
Journal:  Behav Brain Res       Date:  2010-05-21       Impact factor: 3.332

7.  Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency.

Authors:  Jacqueline Hoeppner; Lara Prudente-Morrissey; Sabine Christiane Herpertz; Reiner Benecke; Uwe Walter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-09-19       Impact factor: 5.270

8.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

9.  Use of antidepressants and the risk of Parkinson's disease: a prospective study.

Authors:  A Alonso; L A García Rodríguez; G Logroscino; M A Hernán
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06       Impact factor: 10.154

Review 10.  Psychiatric symptoms in Parkinson's disease.

Authors:  Frank Schneider; Astrid Althaus; Volker Backes; Richard Dodel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.